Prader Willi Syndrome Association Report issue

Foundation Phase 2 Phase 3

Organization Overview

First Clinical Trial
2007
NCT00603109
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Prader-Willi Syndrome Association | PWSAUSA

Active Ingredients

Drugs in Phase 3 Trials (1)

rimonabant (1 trial)

Drugs in Phase 2 Trials (1)

oxytocin (syntocinon) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Prader-Willi Syndrome (Phase 3)

Syndrome (Phase 3)

Weight Gain (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2